SIGLECL1

Across TCGA pan-cancer cohorts, SIGLECL1 RNA is linked to patient survival in 17 of 34 cancer types, making it the most broadly survival-associated SIGLECL1 data layer compared with 3 for mutation status.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher SIGLECL1 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated SIGLECL1 expression acts as an unfavorable survival marker, although some lineages such as SARC and OV show a favorable association.

DLBC, READ, and UVM are the cancer types where SIGLECL1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Tertile	IV	0.213	0.931	.001	92	view →
READ	OS	Tertile	II,III,IV	0.528	0.861	.004	81	view →
UVM	DFS	Tertile	All	0.079	0.746	<.001	54	view →
SARC	OS	Quartile	All	0.900	0.698	<.001	35	view →
MESO	OS	Tertile	All	0.202	0.604	.004	27	view →
KIRC	OS	Tertile	All	0.490	0.680	<.001	25	view →
LUAD	OS	Tertile	II,III,IV	0.297	0.554	.036	18	view →
UCEC	OS	Tertile	All	0.887	0.934	.007	18	view →
LAML	DFS	Median	All	0.481	0.651	.008	18	view →
LIHC	OS	Tertile	All	0.346	0.546	.015	15	view →
OV	OS	Tertile	IV	0.739	0.326	.007	12	view →
KIRP	OS	Tertile	All	0.358	0.755	.011	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 17 lineages.

SIGLECL1–DLBC (OS)

Open the DLBC breakdown →